Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for...
Q1 2026
May 8, 2026
FY 2025
Mar 27, 2026
Q4 2025
Q3 2025
Nov 14, 2025
Q2 2025
Aug 8, 2025